Bulletin Board Archive
Bulletin Board
March 26, 2024
AAN Receives NIH Sub-Award
Allergy & Asthma Network and Blue Marble Health are collaborating on a new virtual asthma coaching platform, with funding support from the National Institutes of Health (NIH). AAN will use Blue Marble’s BREATHE virtual platform for asthma self-management education, with a focus on under-resourced communities.
Affordable Asthma Inhalers
CEO Lynda Mitchell recently spoke with The Lancet Respiratory Medicine about the U.S. Senate investigation into the cost of asthma inhalers. Ensuring access and affordability of medications is one of Allergy & Asthma Network’s key advocacy initiatives. “We support price caps on inhalers,” Lynda says, adding that AAN will monitor if there’s an impact on availability.
Advancing Disparities Research
Allergy & Asthma Network partnered with MITRE on the new Asthma Equity Explorer, a free web-based platform that disseminates data on asthma prevalence and disparities in the United States. Researchers and health professionals can examine how social determinants of health impact asthma outcomes on national, state and local levels.
Bulletin Board
February 27, 2024
Severe Asthma Study Insight
Medical Advisor Vickram Tejwani, MD, and Asthma Coach Leandra Tonweber, PA-C, AE-C, offered their perspective on an eosinophilic asthma study examining the reduced use of inhaled corticosteroids (ICS) among people taking the biologic benralizumab. Dr. Tejwani told Healio.com the findings were “significant” and offer data to support reducing ICS in people who respond well to biologic therapy.
Support for New EPIPEN Act
Allergy & Asthma Network is among patient advocacy groups supporting the EPIPEN Act introduced in Congress by Rep. Maxwell Frost (FL). The legislation would put a price cap on epinephrine auto-injectors. “High out-of-pocket costs for these potentially life-saving medications put Americans with severe allergies at risk for poor health outcomes and deepen health inequities,” CEO Lynda Mitchell says.
Newly Updated Poster for 2024
Our popular Respiratory Treatments poster is newly updated for 2024 – and available now! It contains the newest asthma and COPD medications, including AirSupra®. The poster offers a comparison of the various treatment options, helps doctors and patients easily identify inhalers, and is a great reference for patient education. It’s available in both English and Spanish.
Bulletin Board
January 23, 2024
Allergy & Asthma Network conducted a survey of allergists and patients last year to gauge awareness of Shared Decision-Making (SDM). The survey also aimed to find out what barriers impact SDM use in clinical settings. Among the survey findings: most allergists and patients understand SDM, but did not often use available tools and may need guidance on how to use them.
Trusted Messengers Impact
Allergy & Asthma Network is proud to share the latest results of its signature health equity initiative, Trusted Messengers. Trusted Messengers uses innovative health technology to achieve health equity through its Virtual Asthma Coaching Program. The coaching program has demonstrated improvements in asthma control and quality of life that is sustained at 7-month and 13-month follow-ups.
TikTok and Epi Poster
Tori Martel, our Digital Projects and Social Media Community Manager, presented a poster on epinephrine auto-injector needle fears in TikTik videos during the American College of Allergy, Asthma & Immunology Annual Scientific Meeting Nov. 9-13. The popularity of the videos – they totaled 5+ million “likes” – represents an opportunity to address patient education on epinephrine.